Biognosys secures $5 Million in C round

Bio-Technopark based startup Biognosys offering proteomics solutions has raised $5 million from new and existing investors in an extended series C round. The funds will be used to bring proteomics to the broader life science research market.

Biognosys is a proteomics company offering innovative services and products for highly multiplexed protein quantification. The startup is dedicated to transforming the life sciences with superior proteomics solutions. Biognosys’ next generation technology quantifies proteins with high precision and depth. Its solution relies on mass spectrometry, which allows simultaneous quantification of thousands of proteins in a single experiment.

Biognosys’ contract research services and tools are successfully applied in biomarker research, drug and target discovery, pathway modelling, mechanisms of action studies and many other areas. Its market leading expertise in next-generation proteomics is recognized by top pharma and biotech companies like Novartis, AstraZeneca, Moderna Therapeutics, and world’s leading academic institutions.

The closing of an extended C round is a significant milestone for the startup. The funds will be used to extend its commercial operations and to accelerate the development of next generation proteomics workflows and products for high-content and high-throughput protein analysis.

Press Release